Small scale CDL Stira operates as a small to mid-sized sterile injectable CDMO with 11-50 employees and revenue in the 10–25 million range, suggesting there is room to scale partnerships through longer-term, high-value development and manufacturing engagements.

In house tech The company emphasizes in-house technology platforms and deep technical know-how across formulation development, analytical R&D, IVPT/IVRT, E&L, and regulatory support, presenting an opportunity to offer specialized services or collaborations that complement their core capabilities.

Specialty focus Expertise in small molecules and peptides for sterile injectables indicates potential demand for niche programs, including complex biologics-adjacent formulations, stability studies, and regulatory strategy support tailored to challenging products.

Growth potential With modest headcount and a revenue footprint, Stira could be receptive to strategic partnerships, co-development agreements, or contract manufacturing expansions that accelerate product timelines and leverage their regulatory and microbiology capabilities.

Digital presence A broad tech stack and active professional network (LinkedIn and Google maps) suggest opportunities for outreach through targeted digital campaigns, case studies, and collaboration announcements to build credibility and attract prospective clients seeking specialized CDMO services.